A

Agentek Intelligence Portal

Enter access code to continue

Confidential — Authorized personnel only

M&A Pipeline

Active Targets 5
3-Year Revenue Potential ₪37–60M+
Highest Feasibility ENCO Scientific Score: 9/10

Ready to Evaluate

ENCO Scientific

#1
Consumables M&A

Pure-play consumables, 250+ suppliers, same geography, small team (20), immediate recurring revenue

Feasibility
Strategic Fit
Revenue: $5-15M recurring (3-5yr)

Researching

Danyel Biotech

#2
Genomics M&A

Fills biggest technology gap (NGS/sequencing). Illumina relationship transfer needs careful management

Feasibility
Strategic Fit
Revenue: $8-15M (3yr)

Rigaku (Distribution)

#4
New Principal

XRD/XRF fills materials science gap. Japanese origin aligns with Shimadzu culture. Semiconductor metrology

Feasibility
Strategic Fit
Revenue: ₪10-15M (3yr)

Metrohm (Distribution)

#5
New Principal

Ion chromatography gap. Electrochemistry (Autolab) for battery research. Complements Mettler-Toledo titration

Feasibility
Strategic Fit
Revenue: ₪8-12M (3yr)

Outreach In Progress

Anton Paar (Distribution)

#3
New Principal

Perfect complement: density, rheometry, particle characterization. No Israeli subsidiary. €700M manufacturer

Feasibility
Strategic Fit
Revenue: ₪15-25M (3yr)

Recommended M&A Priority Sequence

1

ENCO Scientific — Consumables/Reagents

Quick integration, immediate recurring revenue, same geography

Highest ROI
2

Danyel Biotech — Genomics/NGS

Fills biggest technology gap (sequencing platforms)

Technology Gap
3

Anton Paar Distribution — New Principal

Perfect portfolio complement, no Israeli subsidiary, €700M manufacturer

Partnership